How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
21st Century Cures Act
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
21st Century Cures Act
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2015 · third_quarter · 3T
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives. Senate draft legislation currently titled "Innovation for Healthier Americans," all provisions pertaining to orphan drug incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2015 · second_quarter · 2A
Source: Senate LDA
21st Century Cures Act
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives. Senate draft legislation currently titled "Innovation for Healthier Americans," all provisions pertaining to orphan drug incentives.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to the implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions pertaining to patient access to treatments. HR 460 "Patients' Access to Treatment Act of 2013," all provisions pertaining to coverage and reimbursement issues for specialty tier drugs. Draft legislation to be called "21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
Keep the Promise to Seniors Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Keep the Promise to Seniors Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Keep the Promise to Seniors Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Keep the Promise to Seniors Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
HR 4160 "The Keep the Promise to Seniors Act of 2014," all provisions relating to protected classes and non-interference provision.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions. Issues relating to patient access to treatments and orphan drug incentives.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions. Issues relating to patient access to treatments and orphan drug incentives.
Patients' Access to Treatments Act of 2013
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues regarding the implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions pertaining to coverage and reimbursement for specialty tier drugs.
Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to draft legislation Tax Reform Act of 2014, all provisions pertaining to orphan drug tax credit. HR 4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions pertaining to IDC corporation list. S 2360 "Stop Corporate Inversions Act of 2014," all provisions pertaining to IDC corporation list.
Stop Corporate Inversions Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Stop Corporate Inversions Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to draft legislation Tax Reform Act of 2014, all provisions pertaining to orphan drug tax credit. HR 4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions pertaining to IDC corporation list. S 2360 "Stop Corporate Inversions Act of 2014," all provisions pertaining to IDC corporation list.
Stop Corporate Inversions Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Stop Corporate Inversions Act of 2014
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
WMD Prevention and Preparedness Act of 2012
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
H.R.2356 "WMD Prevention and Preparedness Act of 2011," all provisions relating to biodefense.
WMD Prevention and Preparedness Act of 2012
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
H.R.2356 "WMD Prevention and Preparedness Act of 2011," all provisions relating to biodefense.
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 and the reauthorization of P.L.108-276 Project Bioshield Act of 2004, provisions relating to biomedical countermeasure procurement strategy and process. H.R. 2405 "Pandemic and All-Hazards Preparedness Reauthorization Act of 2011," all provisions. S.1855, the Pandemic and All-Hazards Preparedness Act Reauthorization of 2011.
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy. Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 and the reauthorization of P.L.108-276 Project Bioshield Act of 2004, provisions relating to biomedical countermeasure procurement strategy and process. H.R. 2405 "Pandemic and All-Hazards Preparedness Reauthorization Act of 2011," all provisions.
WMD Prevention and Preparedness Act of 2010
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
H.R.5498 "WMD Prevention and Preparedness Act of 2010," provisions relating to medical countermeasure development.
Diesel Emissions Reduction Act of 2010
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program, Sunshine Act provisions. S. 3397 "Secure and Responsible Drug Disposal Act of 2010" and H.R.5809 "Safe Drug Disposal Act," all provisions relating to delivery and disposal programs.
Secure and Responsible Drug Disposal Act of 2010
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program, Sunshine Act provisions. S. 3397 "Secure and Responsible Drug Disposal Act of 2010" and H.R.5809 "Safe Drug Disposal Act," all provisions relating to delivery and disposal programs.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 3082 "Fiscal Year 2011 Consolidated Appropriations Act," and Senate Amendment 4885 to H.R. 3082, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 4899 "Supplemental Appropriations Act of 2010," provisions relating to Amendment #2 regarding the Special Reserve Fund and the Public Health and Social Services Emergency Fund.
Patent Reform Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program and biosimilars pathway. S.515 "Patent Reform Act of 2009," provisions relating to the 2010 Managers amendment.
Fairness for Homeowners Act of 2007
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 3082 "Fiscal Year 2011 Consolidated Appropriations Act," and Senate Amendment 4885 to H.R. 3082, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
Montgomery GI Bill Degree Extension Act of 2007
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 3082 "Fiscal Year 2011 Consolidated Appropriations Act," and Senate Amendment 4885 to H.R. 3082, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
Community-Based Mental Health Infrastructure Improvements Act
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
FY2011 defense appropriations, provisions relating to biodefense and anti-botulinum toxin medical countermeasures. FY2011 health and human services (HHS) appropriations, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 4899 "Supplemental Appropriations Act of 2010," provisions relating to Amendment #2 regarding the Special Reserve Fund and the Public Health and Social Services Emergency Fund.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
WMD Prevention and Preparedness Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
WMD Prevention and Preparedness Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy, specifically medical countermeasure strategy. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
WMD Prevention and Preparedness Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
American Recovery and Reinvestment Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security, specifically full funding for medical countermeasure development via the Biomedical Advanced Research and Development Authority (BARDA). Issues regarding critical government needs for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against chemical, biological, nuclear and radiological, and emerging disease threats. Issues relating to biotech job creation and BARDA programs. H.R. 1 / S. 336 "American Recovery and Reinvestment Act of 2009," all provisions relating to BARDA funding. H.R. 1105 "Omnibus Appropriations Act, 2009," all provisions relating to BARDA funding via the Public Health and Social Services Emergency Fund of HHS. Issues regarding Homeland Security Presidential Directive 1, specifically pertaining to White House biodefense organizational structure and to changes within the Office of the Assistant Secretary for Preparedness and Response. Issues relating to bioterrorism stories in the news and to pandemic influenza and BARDA program details. Issues relating to BARDA FY09 priorities overall.
American Recovery and Reinvestment Act of 2009
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues relating to biodefense and national security, specifically full funding for medical countermeasure development via the Biomedical Advanced Research and Development Authority (BARDA). Issues regarding critical government needs for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against chemical, biological, nuclear and radiological, and emerging disease threats. Issues relating to biotech job creation and BARDA programs. H.R. 1 / S. 336 "American Recovery and Reinvestment Act of 2009," all provisions relating to BARDA funding. H.R. 1105 "Omnibus Appropriations Act, 2009," all provisions relating to BARDA funding via the Public Health and Social Services Emergency Fund of HHS. Issues regarding Homeland Security Presidential Directive 1, specifically pertaining to White House biodefense organizational structure and to changes within the Office of the Assistant Secretary for Preparedness and Response. Issues relating to bioterrorism stories in the news and to pandemic influenza and BARDA program details. Issues relating to BARDA FY09 priorities overall.
Job Creation and Unemployment Relief Act of 2008
Client: XOMA CORPORATION (FKA XOMA (US) LLC) · Firm: XOMA CORPORATION (FKA XOMA (US) LLC)
Issues regarding biodefense, specifically regarding national security and medical countermeasure development and manufacture. Issues regarding medical countermeasure stockpiling. Issues regarding the HHS BARDA program and increasing BARDA funding via the Public Health and Social Services Emergency Fund in both the House and Senate economic stimulus bills and the LHHS FY09 omnibus bill. Issues regarding flexible biopharmaceutical manufacturing related to biodefense and increasing HHS BARDA funding in any funding vehicle moving forward (economic stimulus bills and/or LHHS FY09 omnibus bill) regarding the creation of national centers of excellence for flexible manufacturing of medical countermeasures. H.R. 7110, "Job Creation and Unemployment Relief Act of 2008," provisions relating to inserting HHS BARDA funding via the Public Health and Social Services Emergency Fund.
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2015 · second_quarter · Q2
HR 6 "The 21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2015 · first_quarter · Q1
Issues relating to the implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions pertaining to patient access to treatments. HR 460 "Patients' Access to Treatment Act of 2013," all provisions pertaining to coverage and reimbursement issues for specialty tier drugs. Draft legislation to be called "21st Century Cures Act," all provisions pertaining to patient access to treatments and orphan drug incentives.
Issues relating to the draft Tax Reform Act of 2014, all provisions pertaining to an orphan drug tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2014 · fourth_quarter · Q4
Issues relating to the draft Tax Reform Act of 2014, all provisions pertaining to an orphan drug tax credit.
Issues relating to implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions. Issues relating to patient access to treatments and orphan drug incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2014 · third_quarter · Q3
Issues relating to draft legislation Tax Reform Act of 2014, all provisions pertaining to orphan drug tax credit. HR 4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions pertaining to IDC corporation list. S 2360 "Stop Corporate Inversions Act of 2014," all provisions pertaining to IDC corporation list.
Issues relating to implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions. Issues relating to patient access to treatments and orphan drug incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2014 · second_quarter · Q2
Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions relating to an orphan drug tax credit.
HR 4160 "The Keep the Promise to Seniors Act of 2014," all provisions relating to protected classes and non-interference provision.
Issues regarding the implementation of PL 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. HR 460 "Patients' Access to Treatment Act of 2013," all provisions pertaining to coverage and reimbursement for specialty tier drugs.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2014 · second_quarter · RA
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2011 · fourth_quarter · 4T
Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 and the reauthorization of P.L.108-276 Project Bioshield Act of 2004, provisions relating to biomedical countermeasure procurement strategy and process. H.R. 2405 "Pandemic and All-Hazards Preparedness Reauthorization Act of 2011," all provisions. S.1855, the Pandemic and All-Hazards Preparedness Act Reauthorization of 2011.
Filing targets: SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2011 · third_quarter · Q3
Issues pertaining to 2012 appropriations for the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
H.R.2356 "WMD Prevention and Preparedness Act of 2011," all provisions relating to biodefense.
Issues relating to biodefense and national security strategy. Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 and the reauthorization of P.L.108-276 Project Bioshield Act of 2004, provisions relating to biomedical countermeasure procurement strategy and process. H.R. 2405 "Pandemic and All-Hazards Preparedness Reauthorization Act of 2011," all provisions.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2011 · second_quarter · Q2
Issues relating to biodefense and national security strategy. Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 provisions relating to the Public Health Emergency Medical Countermeasure Enterprise. Issues pertaining to the reauthorization of P.L.108-276 Project Bioshield Act of 2004 provisions relating to biomedical countermeasure procurement strategy and process.
S. 23 / H.R. 1249 America Invents Act, provisions specific to biotechnology intellectual property and patent applications.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2011 · first_quarter · Q1
Issues pertaining to P.L.112-4 "Further Continuing Appropriations Amendments, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. Issues pertaining to P.L.112-6 "Additional Continuing Appropriations Amendments, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. Issues pertaining to P.L.112-8 "Further Additional Continuing Appropriations Amendments, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R.1473 "Department of Defense and Full-Year Continuing Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R.1 "Full-Year Continuing Appropriations Act, 2011," and S.AMDT.149, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2010 · fourth_quarter · Q4
Issues relating to biodefense and national security strategy. Issues pertaining to the implementation of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 provisions relating to the Public Health Medical Countermeasure Enterprise. Issues pertaining to the implementation of P.L.108-276 Project Bioshield Act of 2004 provisions relating to biomedical countermeasure procurement strategy and process.
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 3082 "Fiscal Year 2011 Consolidated Appropriations Act," and Senate Amendment 4885 to H.R. 3082, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2010 · third_quarter · Q3
Issues relating to biodefense and national security strategy.
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program, Sunshine Act provisions. S. 3397 "Secure and Responsible Drug Disposal Act of 2010" and H.R.5809 "Safe Drug Disposal Act," all provisions relating to delivery and disposal programs.
S.3686 "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011," provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 3081 "Continuing Appropriations Act, 2011, "provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund. H.R. 4899 "Supplemental Appropriations Act of 2010," provisions relating to Amendment #2 regarding the Special Reserve Fund and the Public Health and Social Services Emergency Fund.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2010 · first_quarter · 1A
FY2011 defense appropriations, provisions relating to biodefense and anti-botulinum toxin medical countermeasures.
Issues relating to biodefense and national security strategy, specifically including Anti-Botulinum toxin medical countermeasures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2010 · second_quarter · Q2
H.R.5498 "WMD Prevention and Preparedness Act of 2010," provisions relating to medical countermeasure development.
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program and biosimilars pathway. S.515 "Patent Reform Act of 2009," provisions relating to the 2010 Managers amendment.
S.3217 "Restoring American Financial Stability Act of 2010," provisions relating to the Sarbanes-Oxley Act of 2002 exemptions.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2010 · first_quarter · Q1
FY2011 defense appropriations, provisions relating to biodefense and anti-botulinum toxin medical countermeasures.
Issues relating to biodefense and national security strategy, specifically including Anti-Botulinum toxin medical countermeasures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · third_quarter · 3A
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
P.L. 111-5 American Recovery and Reinvestment Act 2009, issues pertaining to NIH funding opportunities.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · first_quarter · 1A
Issues relating to biodefense and national security, specifically full funding for medical countermeasure development via the Biomedical Advanced Research and Development Authority (BARDA). Issues regarding critical government needs for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against chemical, biological, nuclear and radiological, and emerging disease threats. Issues relating to biotech job creation and BARDA programs. H.R. 1 / S. 336 "American Recovery and Reinvestment Act of 2009," all provisions relating to BARDA funding. H.R. 1105 "Omnibus Appropriations Act, 2009," all provisions relating to BARDA funding via the Public Health and Social Services Emergency Fund of HHS. Issues regarding Homeland Security Presidential Directive 1, specifically pertaining to White House biodefense organizational structure and to changes within the Office of the Assistant Secretary for Preparedness and Response. Issues relating to bioterrorism stories in the news and to pandemic influenza and BARDA program details. Issues relating to BARDA FY09 priorities overall.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · fourth_quarter · Q4
FY2011 LHHS appropriations, provisions relating to the Public Health and Social Services Emergency Fund.
Issues relating to biodefense and national security strategy, specifically medical countermeasure strategy. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
Filing targets: SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · third_quarter · Q3
P.L. 111-5 American Recovery and Reinvestment Act 2009, issues pertaining to NIH funding opportunities.
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA) and overall medical countermeasure policy. Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Issues related to XOMAs anti-botulinum toxin program. Issues related to Pandemic Influenza National Strategy and Implementation Plan. H.R. 3293 LHHS Appropriations Act 2010, Public Health and Social Services Emergency Fund, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund. S.1649 WMD Prevention and Preparedness Act of 2009, all provisions.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · second_quarter · Q2
Issues relating to biodefense and national security strategy, specifically funding for medical countermeasures via the Biomedical Advanced Research and Development Authority (BARDA). Issues regarding critical government need for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against bioterror agents and pandemic influenza. Presidents Budget FY2010, all provisions related to BARDA funding via the Public Health and Social Services Emergency Fund, HHS.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2009 · first_quarter · Q1
Issues relating to biodefense and national security, specifically full funding for medical countermeasure development via the Biomedical Advanced Research and Development Authority (BARDA). Issues regarding critical government needs for flexible biopharmaceutical manufacturing and advanced development of medical countermeasures against chemical, biological, nuclear and radiological, and emerging disease threats. Issues relating to biotech job creation and BARDA programs. H.R. 1 / S. 336 "American Recovery and Reinvestment Act of 2009," all provisions relating to BARDA funding. H.R. 1105 "Omnibus Appropriations Act, 2009," all provisions relating to BARDA funding via the Public Health and Social Services Emergency Fund of HHS. Issues regarding Homeland Security Presidential Directive 1, specifically pertaining to White House biodefense organizational structure and to changes within the Office of the Assistant Secretary for Preparedness and Response. Issues relating to bioterrorism stories in the news and to pandemic influenza and BARDA program details. Issues relating to BARDA FY09 priorities overall.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2008 · fourth_quarter · Q4
Issues regarding biodefense, specifically regarding national security and medical countermeasure development and manufacture. Issues regarding medical countermeasure stockpiling. Issues regarding the HHS BARDA program and increasing BARDA funding via the Public Health and Social Services Emergency Fund in both the House and Senate economic stimulus bills and the LHHS FY09 omnibus bill. Issues regarding flexible biopharmaceutical manufacturing related to biodefense and increasing HHS BARDA funding in any funding vehicle moving forward (economic stimulus bills and/or LHHS FY09 omnibus bill) regarding the creation of national centers of excellence for flexible manufacturing of medical countermeasures. H.R. 7110, "Job Creation and Unemployment Relief Act of 2008," provisions relating to inserting HHS BARDA funding via the Public Health and Social Services Emergency Fund.
Issues regarding anti-botulism toxin. Issues related to biotechnology research and biotechnology workforce education via the creation of National Life Sciences Academy in CA.
XOMA CORPORATION (FKA XOMA (US) LLC) via XOMA CORPORATION (FKA XOMA (US) LLC)
2008 · third_quarter · Q3
Issues regarding anti-botulism toxin.
Issues regarding biotechnology defense generally and specifically regarding national security; Issues regarding the HHS BARDA program and funding; Issues regarding countermeasure stockpiling; Issues regarding flexible manufacturing related to biodefense counterterrorism. Issues regarding the EOP-generated President's Fiscal Year (FY) 2009 budget amendment request (sent to the House and Senate) to increase funding for BARDA within the Dept. of Health and Human Services.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to general healthcare coverage and reimbursement. Issues relating to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," all provisions. H.R. 460 "Patients Access to Treatment Act of 2013," all provisions. H.R. 4160 "The Keep the Promise to Seniors Act of 2014," all provisions. Issues relating to the Ways and Means Discussion Draft, Tax Reform Act of 2014, all provisions. H.R.4985 "Stop Corporate Expatriation and Invest in America's Infrastructure Act of 2014," all provisions. S.2360 "Stop Corporate Inversions Act of 2014," all provisions.
S. 23 / H.R. 1249 America Invents Act, provisions specific to biotechnology intellectual property and patent applications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.2356 "WMD Prevention and Preparedness Act of 2011," all provisions relating to biodefense.
Issues pertaining to 2012 appropriations for the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health.
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to biodefense and national security strategy. Issues pertaining to the reauthorization of P.L. 109-417 Pandemic and All Hazards Preparedness Act of 2006 provisions relating to the Public Health Emergency Medical Countermeasure Enterprise. Issues pertaining to the reauthorization of P.L.108-276 Project Bioshield Act of 2004 provisions relating to biomedical countermeasure procurement strategy and process.
S. 23 / H.R. 1249 America Invents Act, provisions specific to biotechnology intellectual property and patent applications.
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program, Sunshine Act provisions and 1099 tax reporting requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to the implementation of P.L. 111-148 "Patient Protection and Affordable Care Act of 2010," provisions relating to qualifying therapeutic discovery project program, Sunshine Act provisions, and Biopharmaceutical Manufacturers Fee.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to biodefense and national security strategy, specifically including anti-botulinum toxin medical countermeasures.
FY2011 defense appropriations, provisions relating to biodefense and anti-botulinum toxin medical countermeasures. FY2011 health and human services (HHS) appropriations, provisions relating to the Special Reserve Fund and the Public Health and Social Services Emergency Fund, the Food and Drug Administration, and the National Institutes of Health. H.R. 4899 "Supplemental Appropriations Act of 2010," provisions relating to Amendment #2 regarding the Special Reserve Fund and the Public Health and Social Services Emergency Fund.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE